AlloVir(ALVR) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, dif erentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025 Cash and cash equivalents of $88.4M as of June 30, 2025, expected to fund operations into Q4 2026 PALO ALTO, Calif., August 1 ...